Controlling autoimmunity in sporadic inclusion-body myositis

Neurology. 2006 Jan 24;66(2 Suppl 1):S56-8. doi: 10.1212/01.wnl.0000192110.22621.09.
No abstract available

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Autoimmune Diseases / drug therapy*
  • Chemotaxis, Leukocyte / drug effects
  • Humans
  • Huntington Disease / metabolism
  • Huntington Disease / pathology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Inclusion Bodies / chemistry
  • Inclusion Bodies / immunology
  • Integrin alpha4beta1 / antagonists & inhibitors
  • Lymphocytes / physiology
  • Muscles / pathology
  • Myositis, Inclusion Body / drug therapy*
  • Myositis, Inclusion Body / pathology
  • Natalizumab

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Integrin alpha4beta1
  • Natalizumab